# DSIP for Sleep: What the Research Shows

> DSIP for sleep, by the numbers: a 1977 delta-EEG signature, 25 nmol/kg improving disturbed human sleep, a ~35% rise in rat delta power — and a 2006 review calling the sleep evidence weak.

The delta-EEG signature, the small human sleep trials, the animal slow-wave data — and the honest gaps.

## The short version

DSIP for sleep is the whole reason this peptide is famous — and the reason it is so debated. The name itself, delta sleep-inducing peptide, comes from a 1977 finding that infusing it into the brain made slow "delta" sleep waves stronger [1]. In animals the sleep data is fairly consistent: rats showed about a 35% increase in deep-sleep brain-wave power [9], and cats slept more deeply without losing REM [10]. In people, a few small studies from the 1980s found it helped chronic insomniacs sleep longer with fewer interruptions [2]. But here is the catch: the effect often does not show up until the second hour, a large share of people feel nothing, and a 2006 review called the human sleep evidence weak [3]. DSIP is not approved to treat insomnia or any sleep disorder. This page lays out what the sleep studies actually measured.

## The delta-EEG signature behind the name

DSIP for sleep begins with brain waves. In 1977, infusing the nine-amino-acid peptide into rabbit brains produced a significant, specific enhancement of delta and spindle EEG activity — the slow waves and stage-2 bursts that define deep and consolidating sleep [1]. That is the founding sleep result, and it is genuinely a measured EEG effect, not folklore. The animal record extends it: in rats, DSIP raised neocortical and limbic delta power by roughly 35%, with effects lasting up to 11 hours [9]. Delta power is the most direct EEG proxy for deep, restorative sleep, so an effect of that size in that band is the strongest single piece of the sleep case.

## The human sleep trials

The human DSIP-for-sleep evidence is real but small and old. In six middle-aged chronic insomniacs, a single 25 nmol/kg intravenous dose produced longer sleep, fewer interruptions, slightly more REM, and no daytime sedation — with the sleep-promoting effect appearing in the second hour after the injection [2]. A separate report in severe chronic insomnia found improved sleep efficiency and duration plus significant daytime alertness and performance gains, carrying into the first post-treatment night [7]. In one phase-shifted-insomnia case, DSIP was associated with a roughly 5-hour advance of the sleep phase and full withdrawal from a sleeping pill, with the normalized profile sustained at follow-up [8]. Encouraging numbers — but each study is small, often single-center, and none has been replicated in a modern controlled trial.

## The 2024 sleep result and the cross-species picture

The most recent sleep data uses an engineered form. A 2024 DSIP fusion peptide designed to cross the blood-brain barrier cut average daily wakefulness from about 720 to about 500 minutes — roughly 31% — in PCPA-induced insomnia mice, while restoring melatonin, serotonin, and dopamine and outperforming native DSIP [6]. Subcutaneous DSIP in cats (120 nmol/kg) likewise increased slow-wave sleep without suppressing REM [10], reinforcing that peripherally given DSIP can reach the sleep-relevant circuitry. The pattern across species is consistent in direction even where it is inconsistent in strength: more slow-wave activity, preserved REM.

## The honest gaps in the sleep case

The sleep story has real holes, and naming them is the point of a digest. The signature effect has been inconsistently replicated, and a 2006 review concluded that synthetic analogs — not native DSIP — drove the clearest sleep effects, calling the evidence "extremely poorly documented and still weak" and noting DSIP's brain distribution sits in regions not obviously tied to sleep regulation [3]. There is no large randomized controlled trial of DSIP for sleep, no validated human pharmacokinetics, and a parabolic dose-response that complicates any dosing logic [11][3]. Critically, DSIP is not approved to treat insomnia or any sleep disorder, and persistent sleep problems can signal treatable conditions that deserve real evaluation. The [DSIP research](/research) page lays out every study; [DSIP effects](/effects) covers what people report, including non-response.

---

A data-forward digest of the delta sleep-inducing peptide literature — every figure sourced, every gap named, and no clinic, vendor, or prescription behind the numbers.